Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2019-05-06 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by the board of directors of 金宇生物技术股份有限公司 regarding a share repurchase plan approved at a board meeting and pending approval at the upcoming annual general meeting. It includes detailed information about the top ten shareholders and their shareholdings as of the day before the repurchase decision. The content focuses on the company's decision to repurchase shares and shareholder holdings, which aligns with reporting on share buyback activities. The document length is short (1107 characters), and it is not a full financial report or earnings release. It is not a mere announcement of a report publication but a substantive disclosure about share repurchase and shareholder holdings. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2019-05-06 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress of using idle funds for cash management. It details amounts invested, types of financial products, risk control measures, and the impact on daily operations. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The document is relatively short (1848 characters) and serves as an update on financing activities related to cash management investments. Therefore, it fits best under Capital/Financing Update (CAP).
2019-04-30 Chinese
监事会关于会计政策变更的说明
Regulatory Filings
2019-04-28 Chinese
东北证券股份有限公司关于金宇生物技术股份有限公司2018年度募集资金存放与使用情况的核查意见
Regulatory Filings
2019-04-28 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company 金宇生物技术股份有限公司. It details the reasons for the change, the new accounting standards adopted, and the impact on the company. It includes opinions from independent directors and the supervisory board. The document is relatively short (2043 characters) and does not contain actual financial statements or detailed financial data. It is an announcement of a policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-04-28 Chinese
公司章程（2019年4月修订-1）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 金宇生物技术股份有限公司 (Jinyu Bio-Technology Co., Ltd.). It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and procedures for shareholder meetings. The content is a comprehensive governance document outlining the internal rules, board structure, shareholder meeting procedures, and other governance practices. It is not a financial report, earnings release, or announcement but a governance framework document. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2019-04-28 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.